Myelodysplastic syndrome treated effectively with testosterone enanthate

Iijima, Masashi; Shigehara, Kazuyoshi; Sugimoto, Kazuhiro; Izumi, Kouji; Fukushima, Masato; Maeda, Yuji; Konaka, Hiroyuki; Mizokami, Atsushi; Koh, Eitetsu; Namiki, Mikio

doi:10.1111/j.1442-2042.2011.02757.x

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several recent systematic reviews and meta-analyses did not find clear evidence of increased risk for cardiovascular events in men with testosterone prescription [89,90]. Moreover, low plasma androgen levels in hypogonadal patients have been linked to deficient platelet function, explaining the presence of hemorrhagic diathesis observed in this population [91,92].…”

Section: Overview Of Thrombogenic Potential Of Exogenous Androgensmentioning

confidence: 99%

Effects of Exogenous Androgens on Platelet Activity and Their Thrombogenic Potential in Supraphysiological Administration: A Literature Review

Roşca

Vlădăreanu

Mititelu

et al. 2021

JCM

View full text Add to dashboard Cite

Anabolic androgenic steroids (AAS), simply called “androgens”, represent the most widespread drugs used to enhance performance and appearance in a sporting environment. High-dosage and/or long-term AAS administration has been associated frequently with significant alterations in the cardiovascular system, some of these with severe endpoints. The induction of a prothrombotic state is probably the most life-threatening consequence, suggested by numerous case reports in AAS-abusing athletes, and by a considerable number of human and animal studies assessing the influence of exogenous androgens on hemostasis. Despite over fifty years of research, data regarding the thrombogenic potential of exogenous androgens are still scarce. The main reason is the limited possibility of conducting human prospective studies. However, human observational studies conducted in athletes or patients, in vitro human studies, and animal experiments have pointed out that androgens in supraphysiological doses induce enhanced platelet activity and thrombopoiesis, leading to increased platelet aggregation. If this tendency overlaps previously existing coagulation and/or fibrinolysis dysfunctions, it may lead to a thrombotic diathesis, which could explain the multitude of thromboembolic events reported in the AAS-abusing population. The influence of androgen excess on the platelet activity and fluid–coagulant balance remains a subject of debate, urging for supplementary studies in order to clarify the effects on hemostasis, and to provide new compelling evidence for their claimed thrombogenic potential.

show abstract

Section: Overview Of Thrombogenic Potential Of Exogenous Androgensmentioning

confidence: 99%

Effects of Exogenous Androgens on Platelet Activity and Their Thrombogenic Potential in Supraphysiological Administration: A Literature Review

Roşca

Vlădăreanu

Mititelu

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…TT increases the expression of platelet thromboxane A2 receptors in humans (22). Moreover, TT also increases platelet count in hypogonadal males (23,24). Therefore, TT is associated with an increased risk of thromboembolism (22,25).…”

Section: Introductionmentioning

confidence: 99%

A New Cardiovascular Risk Marker in Men with Hypogonadism: Alanine Aminotransferase

Şahin¹,

Oğuz²,

Tüzün³

et al. 2019

Turk J Endocrinol Metab

View full text Add to dashboard Cite

Objective:We aimed to evaluate the effect of testosterone treatment (TT) on cardiovascular risk markers in male patients with isolated hypogonadotropic hypogonadism (IHH). Material and Methods: We included 50 men with IHH who were admitted to the Kahramanmaraş Sütçü İmam University Endocrinology and Metabolism Clinic and 43 healthy men (the control group). The men in the patient group were compared before and after one year of treatment in terms of total testosterone, fasting plasma glucose, alanine aminotransferases (ALT), high-density lipoprotein-cholesterol (HDL-C), triglycerides (TG), low-density lipoprotein-cholesterol (LDL-C), platelet volume indices [mean platelet volume and platelet distribution width (PDW)], platelet count, and carotid intima-media thickness (CIMT). Moreover, the patient group was compared with the control group. Results: The mean age of the men in the patient and control groups was 31.6 and 29.6 years, respectively. Patients were divided into pre-(patient group 0 ) and posttreatment (patient group 1 ) groups. The levels of CIMT, TG, and ALT were significantly higher and that of HDL-C was significantly lower in the patient group 0 than the control group (p<0.05). Moreover, the level of body mass index, CIMT, ALT, and LDL-C was significantly lower and that of HDL-C, platelet count, and PDW was significantly higher (p<0.05) in the patient group 1 than the patient group 0 . A statistically significant negative correlation was observed between testosterone levels and LDL-C, TG, ALT, and CIMT levels (r=-0.207, p=0.047; r=-0.265, p=0.010; r=-0.266, p=0.010; and r=-0.410, p<0.001, respectively), and a positive correlation was observed between HDL-C and testosterone levels (r=0.270, p=0.009). Conclusion: Our study showed that atherosclerosis risk increases in untreated hypogonadal men. TT has beneficial effects on ALT, CIMT, and lipid profiles. The decrease in ALT after TT may be an indicator of regression in atherosclerosis and a positive response to treatment.Amaç: İzole hipogonadotropik hipogonadizm (İHH) li erkek hastalarda testosteron tedavisi (TT) nin kardiyovasküler risk belirteçleri üzerine etkisini değerlendirmektir. Gereç ve Yöntemler: Kahramanmaraş Sütçü İmam Üniversitesi Endokrinoloji ve Metabolizma polikliniğine başvuran ortalama yaşları 31,6 olan İHH'li 50 erkek hasta ve yaş ortalaması 29,6 olan 43 sağlıklı erkek kontrol çalışmaya dâhil edildi. Hasta grubu tedavi öncesi ve 1 yıl sonra ortalama total testosteron, açlık plazma glukozu, alanin aminotransferaz (ALT), trigliserid (TG), düşük yoğunluklu lipoprotein (LDL), yüksek dansiteli lipoprotein (HDL), trombosit hacim endeksleri [ortalama trombosit hacmi (OTH), trombosit dağılım genişliği (TDG)], trombosit sayısı ve karotid intima-media kalınlığı (KİMK) açısından karşılaştırıldı. Ayrıca hasta grubu, kontrol grubu ile karşılaştırıldı. Bulgular: Hasta grubu TT öncesi (hasta grubu 0 ) ve TT sonrası (hasta grubu 1 ) olarak bölündü. Hasta grubunda kontrol grubuna göre KİMK, LDL, TG ve ALT düzeyleri anlamlı olarak yüksek, HDL düzeyleri an...

show abstract

Testosterone therapy as a novel approach to the management of cytopenias in myelodysplastic neoplasms: a review of literature and case report

Yan,

Rockwell,

Verma

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose To explore the potential of testosterone therapy in managing cytopenias in myelodysplastic neoplasm and investigate the link between hypogonadism and hematologic malignancies. Methods A case of a patient with intermediate-risk myelodysplastic neoplasm and hypogonadism treated with testosterone replacement therapy is presented. Testosterone, prostate specific antigen, and erythropoietin levels were checked prior to therapy initiation and 3 months after. Blood counts were monitored over time. This is followed by a literature review of testosterone use in myelodysplastic neoplasm and the prevalence of hypogonadism in hematologic malignancies. Results The patient showed sustained improvement in anemia with testosterone therapy and reported subjective improvement in his weakness and fatigue. This improvement occurred even in the setting of an undetectable follow up erythropoietin level. His repeat prostate specific antigen levels remained low, while testosterone levels showed marked improvement. The literature review demonstrated positive response rates for testosterone in treating myelodysplastic neoplasm-related cytopenias, and showed a higher incidence of hypogonadism in hematologic malignancies. Conclusion Our review suggests that the use of testosterone in low and intermediate-risk myelodysplastic neoplasm is underexplored and poses to have significant potential as a future therapeutic agent, after careful consideration of risks and benefits. In addition, the incidence of hypogonadism in myelodysplastic neoplasm and its potential impact on exacerbating cytopenias in myelodysplastic neoplasm warrants further investigation.

show abstract

Myelodysplastic syndrome treated effectively with testosterone enanthate

Cited by 4 publications

References 7 publications

Effects of Exogenous Androgens on Platelet Activity and Their Thrombogenic Potential in Supraphysiological Administration: A Literature Review

Effects of Exogenous Androgens on Platelet Activity and Their Thrombogenic Potential in Supraphysiological Administration: A Literature Review

A New Cardiovascular Risk Marker in Men with Hypogonadism: Alanine Aminotransferase

Testosterone therapy as a novel approach to the management of cytopenias in myelodysplastic neoplasms: a review of literature and case report

Contact Info

Product

Resources

About